SU5402 is a potent and selective small molecular vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. SU5402 inhibits embryonic left-right determination and exhibits potent anticancer activity in vitro and in vivo.
|Cell lines||KMS11, UTMC-2, LP1, OPM1, OPM2, KHM11, JJN3, RPMI8226, EJM, K620, H929, U266 and OCI-My5 cell lines|
|Preparation method||KMS11 (provided by MasayoshiNamba), UTMC-2, LP1, OPM1, OPM2, KHM11, JJN3, RPMI8226, EJM, K620, H929 (provided by Leif Bergsagel), U266 and OCI-My5 (provided by Robert Hawley) were grown in Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 10% fetal calf serum (FCS) and 1% Gibco antimycotic/antibiotic (Invitrogen Canada, Ontario, Canada). For proliferation assays, cells were washed and plated in triplicate in IMDM plus 5% FCS and incubated with various concentrations of SU5402. Cells were then analysed by MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] assay (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer’s protocol.|
|Incubation time||48 h|
|Animal models||Spinal cords lesions of zebrafish|
|Dosages||1 μl of 5 μg/μl|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||Stem Cell Reports (2017). SU5402, Figure1 . (AbMole Bioscience)|
|Cell Lines||The mouse ESC lines J1 (ATCC SCRC-1010), CCE, and Jmjd2c KO|
|Results||FGFR inhibition (FGFRi) by SU5402 had little effect compared with LIF (Figure 1A). A two-inhibitor combination (PD0325901 and CHIR99021) and a threeinhibitor combination (PD0325901, CHIR99021, and SU5402) produced robust AP staining of ESCs with a compact colony morphology.|
Stem Cell Reports. 2017 May 9;8(5): 1312–1328.
2i Maintains a Naive Ground State in ESCs through Two Distinct Epigenetic Mechanisms
SU5402 purchased from AbMole
Nectin-1 binds and signals through the fibroblast growth factor receptor.
Bojesen KB, et al. J Biol Chem. 2012 Oct 26;287(44):37420-33. PMID: 22955284.
Characterization and expressional analysis of Dleu7 during Xenopus tropicalis embryogenesis.
Zhu X, et al. Gene. 2012 Nov 1;509(1):77-84. PMID: 22939871.
A retrospective analysis of germline competence in rat embryonic stem cell lines.
Hirabayashi M, et al. Transgenic Res. 2013 Apr;22(2):411-6. PMID: 22875289.
FGF-induced vesicular release of Sonic hedgehog and retinoic acid in leftward nodal flow is critical for left-right determination.
Tanaka Y, et al. Nature. 2005 May 12;435(7039):172-7. PMID: 15889083.
|Related VEGFR/PDGFR Products|
Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 7.68 nM.
Fruquintinib (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively.
SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.
Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret.
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.